The Outcome of Two Protocols Used to Prepare Endometrium for Frozen Embryo Transfer
Infertility, Infertility, Female, Infertility, Male
About this trial
This is an interventional treatment trial for Infertility
Eligibility Criteria
Inclusion Criteria:Inclusion criteria:
- Women aged from18 - 37 years old undergoing FET using good quality blastocysts vitrified on day 5(3 BB and more) (according to Gardner and Schoolcraft 1999) (8).
- Participants having at least one good quality blastocyst (3BB and more) available for transfer after warming.
- Participants having trilaminar endometrium of 9 mm after E2 preparation.
Exclusion Criteria:
- Women younger than 18 or older than 37 years old.
- Women who have uterine abnormality or pathology.
- Women who will not meet the inclusion criteria.
- Women who will refuse to participate in in the study.
Sites / Locations
- Rahem Fertility Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
HRT Plus Aromatase Inhibitor
HRT Only
Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups: Group A (HRT plus AI): will be given aromatase inhibitor for 5 days only (2.5 mg twice daily), along with the oral 6 mg E2. Then, daily intramuscular (IM) P in oil (100 mg IM P) will be started in addition to the daily dose of oral 6 mg E2. In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter.
Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups Group B (HRT only): will be administered daily intramuscular (IM) P in oil (100 mg IM P) in addition to the daily dose of oral 6 mg E2. In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter.